ACP recommends metformin to treat type 2 diabetes based on CE analysis of oral medications

February 6, 2012, American College of Physicians

The American College of Physicians (ACP) recommends that clinicians add metformin as the initial drug treatment for most patients with type 2 diabetes when lifestyle modifications such as diet, exercise, and weight loss have failed to adequately improve high blood sugar.

ACP also recommends that clinicians add a second drug to metformin when treatment with metformin and lifestyle changes fail to control blood sugar levels. Citing insufficient evidence, ACP does not recommend one class of drug over another as a second medication.

The recommendations are part of a new ACP published today in , ACP's flagship journal. ACP developed the guideline based on an analysis of the comparative effectiveness and safety of different classes of oral diabetes drugs approved by the US Food and Drug Administration for the treatment of high blood sugar in people with type 2 diabetes: metformin, sulfonylureas, meglitinides, thiazolidinediones, DPP-4 inhibitors, and GLP-1 .

ACP evaluated the evidence of the impact of high blood sugar levels on clinical outcomes such as body weight, cholesterol and , all-cause mortality, cardiovascular disease and death, neuropathy, and kidney function.

"We found that most diabetes medications reduced blood sugar levels to a similar degree," said Amir Qaseem, MD, FACP, PhD, MHA, Director of Clinical Policy at ACP. "However, metformin is more effective compared to other type 2 diabetes drugs in reducing blood sugar levels when used alone and in combination with other drugs. In addition, metformin reduces body weight and improves cholesterol profiles."

For side effects, the risk for dangerously low was higher with sulfonylureas than with other type 2 . Metformin was associated with fewer side effects than sulfonylureas.

The evidence was insufficient to show any difference in effectiveness between various medications across subgroups of adults, such as age, sex, or race.

Best Practice Advice

The guideline includes a Best Practice Advice section to help clinicians practice high value, cost-conscious care. ACP recommends prescribing generic metformin because it has better effectiveness than the majority of the other medications; is associated with fewer adverse effects, including that it does not result in weight gain; and is less expensive.

Patient Education

The guideline notes that good management of type 2 diabetes includes patient education. A patient summary of the guideline is available at http://www.annals.org/content/156/3/I-36.full.

Explore further: Researchers test a drug-exercise program designed to prevent type 2 diabetes

Related Stories

Researchers test a drug-exercise program designed to prevent type 2 diabetes

December 6, 2011
(Medical Xpress) -- Kinesiology researcher Barry Braun of the University of Massachusetts Amherst and colleagues recently reported unexpected results of a study suggesting that exercise and one of the most commonly prescribed ...

Recommended for you

Genetic discovery may help better identify children at risk for type 1 diabetes

January 17, 2018
Six novel chromosomal regions identified by scientists leading a large, prospective study of children at risk for type 1 diabetes will enable the discovery of more genes that cause the disease and more targets for treating ...

Thirty-year study shows women who breastfeed for six months or more reduce their diabetes risk

January 16, 2018
In a long-term national study, breastfeeding for six months or longer cuts the risk of developing type 2 diabetes nearly in half for women throughout their childbearing years, according to new Kaiser Permanente research published ...

Women who have gestational diabetes in pregnancy are at higher risk of future health issues

January 16, 2018
Women who have gestational diabetes mellitus (GDM) during pregnancy have a higher than usual risk of developing type 2 diabetes, hypertension, and ischemic heart disease in the future, according to new research led by the ...

Diabetes gene found that causes low and high blood sugar levels in the same family

January 15, 2018
A study of families with rare blood sugar conditions has revealed a new gene thought to be critical in the regulation of insulin, the key hormone in diabetes.

Discovery could lead to new therapies for diabetics

January 12, 2018
New research by MDI Biological Laboratory scientist Sandra Rieger, Ph.D., and her team has demonstrated that an enzyme she had previously identified as playing a role in peripheral neuropathy induced by cancer chemotherapy ...

Enzyme shown to regulate inflammation and metabolism in fat tissue

January 11, 2018
The human body has two primary kinds of fat—white fat, which stores excess calories and is associated with obesity, and brown fat, which burns calories in order to produce heat and has garnered interest as a potential means ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.